nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—ABCB1—peripheral nervous system neoplasm	0.281	1	CbGaD
Paroxetine—CYP2B6—Tretinoin—peripheral nervous system neoplasm	0.055	0.167	CbGbCtD
Paroxetine—CYP2C8—Tretinoin—peripheral nervous system neoplasm	0.0417	0.126	CbGbCtD
Paroxetine—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0304	0.0921	CbGbCtD
Paroxetine—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0304	0.0921	CbGbCtD
Paroxetine—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0291	0.0882	CbGbCtD
Paroxetine—CYP2B6—Cisplatin—peripheral nervous system neoplasm	0.0236	0.0715	CbGbCtD
Paroxetine—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.021	0.0638	CbGbCtD
Paroxetine—CYP2C8—Etoposide—peripheral nervous system neoplasm	0.0175	0.0532	CbGbCtD
Paroxetine—CYP2B6—Doxorubicin—peripheral nervous system neoplasm	0.0158	0.0479	CbGbCtD
Paroxetine—ABCB1—Vincristine—peripheral nervous system neoplasm	0.013	0.0393	CbGbCtD
Paroxetine—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.0125	0.0378	CbGbCtD
Paroxetine—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0121	0.0367	CbGbCtD
Paroxetine—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0119	0.036	CbGbCtD
Paroxetine—TACR1—trigeminal nerve—peripheral nervous system neoplasm	0.0102	0.154	CbGeAlD
Paroxetine—TACR1—vagus nerve—peripheral nervous system neoplasm	0.00956	0.144	CbGeAlD
Paroxetine—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.0081	0.0246	CbGbCtD
Paroxetine—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00763	0.0232	CbGbCtD
Paroxetine—TACR1—cranial nerve—peripheral nervous system neoplasm	0.00728	0.11	CbGeAlD
Paroxetine—HTR2A—phrenic nerve—peripheral nervous system neoplasm	0.00682	0.103	CbGeAlD
Paroxetine—TACR1—nerve—peripheral nervous system neoplasm	0.00373	0.0562	CbGeAlD
Paroxetine—TACR1—ganglion—peripheral nervous system neoplasm	0.00369	0.0555	CbGeAlD
Paroxetine—HTR2A—trigeminal nerve—peripheral nervous system neoplasm	0.00249	0.0375	CbGeAlD
Paroxetine—HTR2A—vagus nerve—peripheral nervous system neoplasm	0.00233	0.0351	CbGeAlD
Paroxetine—SLC6A3—nerve—peripheral nervous system neoplasm	0.00188	0.0283	CbGeAlD
Paroxetine—SLC6A3—ganglion—peripheral nervous system neoplasm	0.00185	0.0279	CbGeAlD
Paroxetine—HTR2A—cranial nerve—peripheral nervous system neoplasm	0.00178	0.0267	CbGeAlD
Paroxetine—HTR2A—pons—peripheral nervous system neoplasm	0.00176	0.0264	CbGeAlD
Paroxetine—SLC6A4—ganglion—peripheral nervous system neoplasm	0.0017	0.0256	CbGeAlD
Paroxetine—TACR1—brainstem—peripheral nervous system neoplasm	0.0016	0.0241	CbGeAlD
Paroxetine—SLC6A2—nerve—peripheral nervous system neoplasm	0.00151	0.0228	CbGeAlD
Paroxetine—SLC6A2—ganglion—peripheral nervous system neoplasm	0.0015	0.0225	CbGeAlD
Paroxetine—HTR2A—nerve—peripheral nervous system neoplasm	0.00091	0.0137	CbGeAlD
Paroxetine—HTR2A—ganglion—peripheral nervous system neoplasm	0.000899	0.0135	CbGeAlD
Paroxetine—SLC6A3—brainstem—peripheral nervous system neoplasm	0.000806	0.0121	CbGeAlD
Paroxetine—CHRM1—parotid gland—peripheral nervous system neoplasm	0.000784	0.0118	CbGeAlD
Paroxetine—SLC6A4—brainstem—peripheral nervous system neoplasm	0.000739	0.0111	CbGeAlD
Paroxetine—SLC6A2—brainstem—peripheral nervous system neoplasm	0.00065	0.00979	CbGeAlD
Paroxetine—SLC6A3—cerebellum—peripheral nervous system neoplasm	0.000397	0.00598	CbGeAlD
Paroxetine—HTR2A—brainstem—peripheral nervous system neoplasm	0.000391	0.00588	CbGeAlD
Paroxetine—CYP2D6—brainstem—peripheral nervous system neoplasm	0.000356	0.00536	CbGeAlD
Paroxetine—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000289	0.00436	CbGeAlD
Paroxetine—HTR2A—cerebellum—peripheral nervous system neoplasm	0.000193	0.0029	CbGeAlD
Paroxetine—CYP2D6—cerebellum—peripheral nervous system neoplasm	0.000176	0.00264	CbGeAlD
Paroxetine—ABCB1—cerebellum—peripheral nervous system neoplasm	0.000126	0.0019	CbGeAlD
Paroxetine—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	5.61e-05	0.000195	CcSEcCtD
Paroxetine—Rash—Dactinomycin—peripheral nervous system neoplasm	5.61e-05	0.000195	CcSEcCtD
Paroxetine—Decreased appetite—Etoposide—peripheral nervous system neoplasm	5.6e-05	0.000195	CcSEcCtD
Paroxetine—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	5.58e-05	0.000194	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	5.56e-05	0.000193	CcSEcCtD
Paroxetine—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	5.56e-05	0.000193	CcSEcCtD
Paroxetine—Fatigue—Etoposide—peripheral nervous system neoplasm	5.55e-05	0.000193	CcSEcCtD
Paroxetine—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	5.55e-05	0.000193	CcSEcCtD
Paroxetine—Jaundice—Epirubicin—peripheral nervous system neoplasm	5.52e-05	0.000192	CcSEcCtD
Paroxetine—Stomatitis—Epirubicin—peripheral nervous system neoplasm	5.52e-05	0.000192	CcSEcCtD
Paroxetine—Constipation—Etoposide—peripheral nervous system neoplasm	5.51e-05	0.000191	CcSEcCtD
Paroxetine—Pain—Etoposide—peripheral nervous system neoplasm	5.51e-05	0.000191	CcSEcCtD
Paroxetine—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	5.5e-05	0.000191	CcSEcCtD
Paroxetine—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	5.5e-05	0.000191	CcSEcCtD
Paroxetine—Dysuria—Doxorubicin—peripheral nervous system neoplasm	5.49e-05	0.000191	CcSEcCtD
Paroxetine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	5.46e-05	0.00019	CcSEcCtD
Paroxetine—Diarrhoea—Vincristine—peripheral nervous system neoplasm	5.44e-05	0.000189	CcSEcCtD
Paroxetine—Sweating—Epirubicin—peripheral nervous system neoplasm	5.43e-05	0.000189	CcSEcCtD
Paroxetine—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	5.43e-05	0.000189	CcSEcCtD
Paroxetine—Haematuria—Epirubicin—peripheral nervous system neoplasm	5.4e-05	0.000188	CcSEcCtD
Paroxetine—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	5.36e-05	0.000186	CcSEcCtD
Paroxetine—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	5.36e-05	0.000186	CcSEcCtD
Paroxetine—Weight increased—Doxorubicin—peripheral nervous system neoplasm	5.35e-05	0.000186	CcSEcCtD
Paroxetine—Epistaxis—Epirubicin—peripheral nervous system neoplasm	5.34e-05	0.000186	CcSEcCtD
Paroxetine—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	5.32e-05	0.000185	CcSEcCtD
Paroxetine—Sinusitis—Epirubicin—peripheral nervous system neoplasm	5.31e-05	0.000185	CcSEcCtD
Paroxetine—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	5.31e-05	0.000184	CcSEcCtD
Paroxetine—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	5.3e-05	0.000184	CcSEcCtD
Paroxetine—Nausea—Dactinomycin—peripheral nervous system neoplasm	5.29e-05	0.000184	CcSEcCtD
Paroxetine—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	5.28e-05	0.000184	CcSEcCtD
Paroxetine—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	5.27e-05	0.000183	CcSEcCtD
Paroxetine—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	5.27e-05	0.000183	CcSEcCtD
Paroxetine—Dizziness—Vincristine—peripheral nervous system neoplasm	5.26e-05	0.000183	CcSEcCtD
Paroxetine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	5.25e-05	0.000182	CcSEcCtD
Paroxetine—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	5.24e-05	0.000182	CcSEcCtD
Paroxetine—Rash—Alitretinoin—peripheral nervous system neoplasm	5.2e-05	0.000181	CcSEcCtD
Paroxetine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	5.2e-05	0.000181	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	5.19e-05	0.00018	CcSEcCtD
Paroxetine—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	5.18e-05	0.00018	CcSEcCtD
Paroxetine—Bradycardia—Epirubicin—peripheral nervous system neoplasm	5.17e-05	0.00018	CcSEcCtD
Paroxetine—Headache—Alitretinoin—peripheral nervous system neoplasm	5.17e-05	0.00018	CcSEcCtD
Paroxetine—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	5.14e-05	0.000178	CcSEcCtD
Paroxetine—Urticaria—Etoposide—peripheral nervous system neoplasm	5.12e-05	0.000178	CcSEcCtD
Paroxetine—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	5.11e-05	0.000177	CcSEcCtD
Paroxetine—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	5.11e-05	0.000177	CcSEcCtD
Paroxetine—Jaundice—Doxorubicin—peripheral nervous system neoplasm	5.11e-05	0.000177	CcSEcCtD
Paroxetine—Rhinitis—Epirubicin—peripheral nervous system neoplasm	5.1e-05	0.000177	CcSEcCtD
Paroxetine—Abdominal pain—Etoposide—peripheral nervous system neoplasm	5.09e-05	0.000177	CcSEcCtD
Paroxetine—Body temperature increased—Etoposide—peripheral nervous system neoplasm	5.09e-05	0.000177	CcSEcCtD
Paroxetine—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	5.09e-05	0.000177	CcSEcCtD
Paroxetine—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	5.09e-05	0.000177	CcSEcCtD
Paroxetine—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	5.08e-05	0.000177	CcSEcCtD
Paroxetine—Hepatitis—Epirubicin—peripheral nervous system neoplasm	5.08e-05	0.000177	CcSEcCtD
Paroxetine—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	5.06e-05	0.000176	CcSEcCtD
Paroxetine—Vomiting—Vincristine—peripheral nervous system neoplasm	5.06e-05	0.000176	CcSEcCtD
Paroxetine—Asthenia—Cisplatin—peripheral nervous system neoplasm	5.05e-05	0.000175	CcSEcCtD
Paroxetine—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	5.05e-05	0.000175	CcSEcCtD
Paroxetine—Sweating—Doxorubicin—peripheral nervous system neoplasm	5.02e-05	0.000174	CcSEcCtD
Paroxetine—Rash—Vincristine—peripheral nervous system neoplasm	5.01e-05	0.000174	CcSEcCtD
Paroxetine—Dermatitis—Vincristine—peripheral nervous system neoplasm	5.01e-05	0.000174	CcSEcCtD
Paroxetine—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	5.01e-05	0.000174	CcSEcCtD
Paroxetine—Haematuria—Doxorubicin—peripheral nervous system neoplasm	5e-05	0.000174	CcSEcCtD
Paroxetine—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	5e-05	0.000174	CcSEcCtD
Paroxetine—Headache—Vincristine—peripheral nervous system neoplasm	4.98e-05	0.000173	CcSEcCtD
Paroxetine—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	4.96e-05	0.000172	CcSEcCtD
Paroxetine—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	4.94e-05	0.000172	CcSEcCtD
Paroxetine—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	4.92e-05	0.000171	CcSEcCtD
Paroxetine—Nausea—Alitretinoin—peripheral nervous system neoplasm	4.9e-05	0.00017	CcSEcCtD
Paroxetine—Visual impairment—Epirubicin—peripheral nervous system neoplasm	4.9e-05	0.00017	CcSEcCtD
Paroxetine—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	4.89e-05	0.00017	CcSEcCtD
Paroxetine—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	4.81e-05	0.000167	CcSEcCtD
Paroxetine—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	4.81e-05	0.000167	CcSEcCtD
Paroxetine—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	4.79e-05	0.000166	CcSEcCtD
Paroxetine—Eye disorder—Epirubicin—peripheral nervous system neoplasm	4.75e-05	0.000165	CcSEcCtD
Paroxetine—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	4.75e-05	0.000165	CcSEcCtD
Paroxetine—Tinnitus—Epirubicin—peripheral nervous system neoplasm	4.74e-05	0.000165	CcSEcCtD
Paroxetine—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	4.73e-05	0.000164	CcSEcCtD
Paroxetine—Nausea—Vincristine—peripheral nervous system neoplasm	4.72e-05	0.000164	CcSEcCtD
Paroxetine—Flushing—Epirubicin—peripheral nervous system neoplasm	4.72e-05	0.000164	CcSEcCtD
Paroxetine—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	4.72e-05	0.000164	CcSEcCtD
Paroxetine—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	4.72e-05	0.000164	CcSEcCtD
Paroxetine—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	4.7e-05	0.000163	CcSEcCtD
Paroxetine—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	4.7e-05	0.000163	CcSEcCtD
Paroxetine—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	4.68e-05	0.000163	CcSEcCtD
Paroxetine—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	4.67e-05	0.000162	CcSEcCtD
Paroxetine—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	4.63e-05	0.000161	CcSEcCtD
Paroxetine—Asthenia—Etoposide—peripheral nervous system neoplasm	4.62e-05	0.000161	CcSEcCtD
Paroxetine—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	4.62e-05	0.000161	CcSEcCtD
Paroxetine—Angiopathy—Epirubicin—peripheral nervous system neoplasm	4.61e-05	0.00016	CcSEcCtD
Paroxetine—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	4.59e-05	0.000159	CcSEcCtD
Paroxetine—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	4.58e-05	0.000159	CcSEcCtD
Paroxetine—Chills—Epirubicin—peripheral nervous system neoplasm	4.56e-05	0.000158	CcSEcCtD
Paroxetine—Pruritus—Etoposide—peripheral nervous system neoplasm	4.56e-05	0.000158	CcSEcCtD
Paroxetine—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	4.54e-05	0.000158	CcSEcCtD
Paroxetine—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	4.53e-05	0.000157	CcSEcCtD
Paroxetine—Alopecia—Epirubicin—peripheral nervous system neoplasm	4.49e-05	0.000156	CcSEcCtD
Paroxetine—Vomiting—Cisplatin—peripheral nervous system neoplasm	4.47e-05	0.000155	CcSEcCtD
Paroxetine—Mental disorder—Epirubicin—peripheral nervous system neoplasm	4.45e-05	0.000155	CcSEcCtD
Paroxetine—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	4.45e-05	0.000154	CcSEcCtD
Paroxetine—Rash—Cisplatin—peripheral nervous system neoplasm	4.43e-05	0.000154	CcSEcCtD
Paroxetine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	4.43e-05	0.000154	CcSEcCtD
Paroxetine—Malnutrition—Epirubicin—peripheral nervous system neoplasm	4.42e-05	0.000154	CcSEcCtD
Paroxetine—Erythema—Epirubicin—peripheral nervous system neoplasm	4.42e-05	0.000154	CcSEcCtD
Paroxetine—Diarrhoea—Etoposide—peripheral nervous system neoplasm	4.41e-05	0.000153	CcSEcCtD
Paroxetine—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	4.4e-05	0.000153	CcSEcCtD
Paroxetine—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	4.39e-05	0.000152	CcSEcCtD
Paroxetine—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	4.37e-05	0.000152	CcSEcCtD
Paroxetine—Flushing—Doxorubicin—peripheral nervous system neoplasm	4.37e-05	0.000152	CcSEcCtD
Paroxetine—Flatulence—Epirubicin—peripheral nervous system neoplasm	4.36e-05	0.000151	CcSEcCtD
Paroxetine—Tension—Epirubicin—peripheral nervous system neoplasm	4.34e-05	0.000151	CcSEcCtD
Paroxetine—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	4.33e-05	0.000151	CcSEcCtD
Paroxetine—Nervousness—Epirubicin—peripheral nervous system neoplasm	4.3e-05	0.000149	CcSEcCtD
Paroxetine—Back pain—Epirubicin—peripheral nervous system neoplasm	4.28e-05	0.000149	CcSEcCtD
Paroxetine—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	4.27e-05	0.000148	CcSEcCtD
Paroxetine—Dizziness—Etoposide—peripheral nervous system neoplasm	4.26e-05	0.000148	CcSEcCtD
Paroxetine—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	4.25e-05	0.000148	CcSEcCtD
Paroxetine—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	4.25e-05	0.000148	CcSEcCtD
Paroxetine—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	4.24e-05	0.000147	CcSEcCtD
Paroxetine—Chills—Doxorubicin—peripheral nervous system neoplasm	4.22e-05	0.000147	CcSEcCtD
Paroxetine—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	4.2e-05	0.000146	CcSEcCtD
Paroxetine—Nausea—Cisplatin—peripheral nervous system neoplasm	4.18e-05	0.000145	CcSEcCtD
Paroxetine—Vision blurred—Epirubicin—peripheral nervous system neoplasm	4.17e-05	0.000145	CcSEcCtD
Paroxetine—Alopecia—Doxorubicin—peripheral nervous system neoplasm	4.16e-05	0.000144	CcSEcCtD
Paroxetine—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	4.12e-05	0.000143	CcSEcCtD
Paroxetine—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	4.11e-05	0.000143	CcSEcCtD
Paroxetine—Vomiting—Etoposide—peripheral nervous system neoplasm	4.1e-05	0.000142	CcSEcCtD
Paroxetine—Erythema—Doxorubicin—peripheral nervous system neoplasm	4.09e-05	0.000142	CcSEcCtD
Paroxetine—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	4.09e-05	0.000142	CcSEcCtD
Paroxetine—Anaemia—Epirubicin—peripheral nervous system neoplasm	4.09e-05	0.000142	CcSEcCtD
Paroxetine—Agitation—Epirubicin—peripheral nervous system neoplasm	4.07e-05	0.000141	CcSEcCtD
Paroxetine—Rash—Etoposide—peripheral nervous system neoplasm	4.06e-05	0.000141	CcSEcCtD
Paroxetine—Dermatitis—Etoposide—peripheral nervous system neoplasm	4.06e-05	0.000141	CcSEcCtD
Paroxetine—Headache—Etoposide—peripheral nervous system neoplasm	4.04e-05	0.00014	CcSEcCtD
Paroxetine—Flatulence—Doxorubicin—peripheral nervous system neoplasm	4.03e-05	0.00014	CcSEcCtD
Paroxetine—Tension—Doxorubicin—peripheral nervous system neoplasm	4.02e-05	0.00014	CcSEcCtD
Paroxetine—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	4.01e-05	0.000139	CcSEcCtD
Paroxetine—Malaise—Epirubicin—peripheral nervous system neoplasm	3.99e-05	0.000139	CcSEcCtD
Paroxetine—Nervousness—Doxorubicin—peripheral nervous system neoplasm	3.98e-05	0.000138	CcSEcCtD
Paroxetine—Vertigo—Epirubicin—peripheral nervous system neoplasm	3.98e-05	0.000138	CcSEcCtD
Paroxetine—Syncope—Epirubicin—peripheral nervous system neoplasm	3.97e-05	0.000138	CcSEcCtD
Paroxetine—Leukopenia—Epirubicin—peripheral nervous system neoplasm	3.96e-05	0.000138	CcSEcCtD
Paroxetine—Back pain—Doxorubicin—peripheral nervous system neoplasm	3.96e-05	0.000138	CcSEcCtD
Paroxetine—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	3.94e-05	0.000137	CcSEcCtD
Paroxetine—Palpitations—Epirubicin—peripheral nervous system neoplasm	3.91e-05	0.000136	CcSEcCtD
Paroxetine—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	3.89e-05	0.000135	CcSEcCtD
Paroxetine—Cough—Epirubicin—peripheral nervous system neoplasm	3.86e-05	0.000134	CcSEcCtD
Paroxetine—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	3.86e-05	0.000134	CcSEcCtD
Paroxetine—Convulsion—Epirubicin—peripheral nervous system neoplasm	3.83e-05	0.000133	CcSEcCtD
Paroxetine—Nausea—Etoposide—peripheral nervous system neoplasm	3.83e-05	0.000133	CcSEcCtD
Paroxetine—Hypertension—Epirubicin—peripheral nervous system neoplasm	3.82e-05	0.000133	CcSEcCtD
Paroxetine—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	3.8e-05	0.000132	CcSEcCtD
Paroxetine—Anaemia—Doxorubicin—peripheral nervous system neoplasm	3.78e-05	0.000131	CcSEcCtD
Paroxetine—Arthralgia—Epirubicin—peripheral nervous system neoplasm	3.77e-05	0.000131	CcSEcCtD
Paroxetine—Chest pain—Epirubicin—peripheral nervous system neoplasm	3.77e-05	0.000131	CcSEcCtD
Paroxetine—Myalgia—Epirubicin—peripheral nervous system neoplasm	3.77e-05	0.000131	CcSEcCtD
Paroxetine—Agitation—Doxorubicin—peripheral nervous system neoplasm	3.76e-05	0.000131	CcSEcCtD
Paroxetine—Anxiety—Epirubicin—peripheral nervous system neoplasm	3.75e-05	0.00013	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	3.74e-05	0.00013	CcSEcCtD
Paroxetine—Discomfort—Epirubicin—peripheral nervous system neoplasm	3.72e-05	0.000129	CcSEcCtD
Paroxetine—Malaise—Doxorubicin—peripheral nervous system neoplasm	3.69e-05	0.000128	CcSEcCtD
Paroxetine—Dry mouth—Epirubicin—peripheral nervous system neoplasm	3.68e-05	0.000128	CcSEcCtD
Paroxetine—Vertigo—Doxorubicin—peripheral nervous system neoplasm	3.68e-05	0.000128	CcSEcCtD
Paroxetine—Syncope—Doxorubicin—peripheral nervous system neoplasm	3.67e-05	0.000128	CcSEcCtD
Paroxetine—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	3.66e-05	0.000127	CcSEcCtD
Paroxetine—Confusional state—Epirubicin—peripheral nervous system neoplasm	3.64e-05	0.000126	CcSEcCtD
Paroxetine—Palpitations—Doxorubicin—peripheral nervous system neoplasm	3.62e-05	0.000126	CcSEcCtD
Paroxetine—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	3.61e-05	0.000125	CcSEcCtD
Paroxetine—Oedema—Epirubicin—peripheral nervous system neoplasm	3.61e-05	0.000125	CcSEcCtD
Paroxetine—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	3.6e-05	0.000125	CcSEcCtD
Paroxetine—Infection—Epirubicin—peripheral nervous system neoplasm	3.59e-05	0.000125	CcSEcCtD
Paroxetine—Cough—Doxorubicin—peripheral nervous system neoplasm	3.57e-05	0.000124	CcSEcCtD
Paroxetine—Shock—Epirubicin—peripheral nervous system neoplasm	3.55e-05	0.000123	CcSEcCtD
Paroxetine—Convulsion—Doxorubicin—peripheral nervous system neoplasm	3.55e-05	0.000123	CcSEcCtD
Paroxetine—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	3.54e-05	0.000123	CcSEcCtD
Paroxetine—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	3.54e-05	0.000123	CcSEcCtD
Paroxetine—Hypertension—Doxorubicin—peripheral nervous system neoplasm	3.53e-05	0.000123	CcSEcCtD
Paroxetine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	3.52e-05	0.000122	CcSEcCtD
Paroxetine—Skin disorder—Epirubicin—peripheral nervous system neoplasm	3.51e-05	0.000122	CcSEcCtD
Paroxetine—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	3.49e-05	0.000121	CcSEcCtD
Paroxetine—Myalgia—Doxorubicin—peripheral nervous system neoplasm	3.49e-05	0.000121	CcSEcCtD
Paroxetine—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	3.49e-05	0.000121	CcSEcCtD
Paroxetine—Chest pain—Doxorubicin—peripheral nervous system neoplasm	3.49e-05	0.000121	CcSEcCtD
Paroxetine—Anxiety—Doxorubicin—peripheral nervous system neoplasm	3.47e-05	0.000121	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	3.46e-05	0.00012	CcSEcCtD
Paroxetine—Discomfort—Doxorubicin—peripheral nervous system neoplasm	3.44e-05	0.00012	CcSEcCtD
Paroxetine—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	3.41e-05	0.000118	CcSEcCtD
Paroxetine—Hypotension—Epirubicin—peripheral nervous system neoplasm	3.37e-05	0.000117	CcSEcCtD
Paroxetine—Confusional state—Doxorubicin—peripheral nervous system neoplasm	3.37e-05	0.000117	CcSEcCtD
Paroxetine—Oedema—Doxorubicin—peripheral nervous system neoplasm	3.34e-05	0.000116	CcSEcCtD
Paroxetine—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	3.34e-05	0.000116	CcSEcCtD
Paroxetine—Infection—Doxorubicin—peripheral nervous system neoplasm	3.32e-05	0.000115	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	3.29e-05	0.000114	CcSEcCtD
Paroxetine—Shock—Doxorubicin—peripheral nervous system neoplasm	3.29e-05	0.000114	CcSEcCtD
Paroxetine—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	3.28e-05	0.000114	CcSEcCtD
Paroxetine—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	3.27e-05	0.000114	CcSEcCtD
Paroxetine—Insomnia—Epirubicin—peripheral nervous system neoplasm	3.27e-05	0.000113	CcSEcCtD
Paroxetine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	3.26e-05	0.000113	CcSEcCtD
Paroxetine—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	3.25e-05	0.000113	CcSEcCtD
Paroxetine—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	3.24e-05	0.000113	CcSEcCtD
Paroxetine—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	3.23e-05	0.000112	CcSEcCtD
Paroxetine—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	3.22e-05	0.000112	CcSEcCtD
Paroxetine—Somnolence—Epirubicin—peripheral nervous system neoplasm	3.21e-05	0.000112	CcSEcCtD
Paroxetine—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	3.18e-05	0.00011	CcSEcCtD
Paroxetine—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	3.14e-05	0.000109	CcSEcCtD
Paroxetine—Hypotension—Doxorubicin—peripheral nervous system neoplasm	3.12e-05	0.000108	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	3.12e-05	0.000108	CcSEcCtD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	3.11e-05	0.000896	CbGpPWpGaD
Paroxetine—Fatigue—Epirubicin—peripheral nervous system neoplasm	3.11e-05	0.000108	CcSEcCtD
Paroxetine—CHRM2—Regulation of Actin Cytoskeleton—NRAS—peripheral nervous system neoplasm	3.1e-05	0.000892	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.1e-05	0.000891	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.09e-05	0.000889	CbGpPWpGaD
Paroxetine—Pain—Epirubicin—peripheral nervous system neoplasm	3.09e-05	0.000107	CcSEcCtD
Paroxetine—Constipation—Epirubicin—peripheral nervous system neoplasm	3.09e-05	0.000107	CcSEcCtD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	3.06e-05	0.000879	CbGpPWpGaD
Paroxetine—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	3.04e-05	0.000106	CcSEcCtD
Paroxetine—CHRM4—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	3.03e-05	0.000872	CbGpPWpGaD
Paroxetine—Insomnia—Doxorubicin—peripheral nervous system neoplasm	3.02e-05	0.000105	CcSEcCtD
Paroxetine—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	3e-05	0.000104	CcSEcCtD
Paroxetine—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	2.98e-05	0.000103	CcSEcCtD
Paroxetine—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	2.98e-05	0.000103	CcSEcCtD
Paroxetine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	2.97e-05	0.000103	CcSEcCtD
Paroxetine—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	2.95e-05	0.000103	CcSEcCtD
Paroxetine—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	2.94e-05	0.000102	CcSEcCtD
Paroxetine—CYP2C8—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.93e-05	0.000843	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GNS—peripheral nervous system neoplasm	2.91e-05	0.000837	CbGpPWpGaD
Paroxetine—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	2.9e-05	0.000101	CcSEcCtD
Paroxetine—HTR2A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	2.9e-05	0.000835	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.9e-05	0.000835	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	2.89e-05	0.000831	CbGpPWpGaD
Paroxetine—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	2.88e-05	0.0001	CcSEcCtD
Paroxetine—Fatigue—Doxorubicin—peripheral nervous system neoplasm	2.88e-05	0.0001	CcSEcCtD
Paroxetine—CHRM3—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	2.88e-05	0.000828	CbGpPWpGaD
Paroxetine—Urticaria—Epirubicin—peripheral nervous system neoplasm	2.87e-05	9.97e-05	CcSEcCtD
Paroxetine—Constipation—Doxorubicin—peripheral nervous system neoplasm	2.86e-05	9.93e-05	CcSEcCtD
Paroxetine—Pain—Doxorubicin—peripheral nervous system neoplasm	2.86e-05	9.93e-05	CcSEcCtD
Paroxetine—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	2.85e-05	9.92e-05	CcSEcCtD
Paroxetine—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	2.85e-05	9.92e-05	CcSEcCtD
Paroxetine—CHRM2—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	2.85e-05	0.00082	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—NME1—peripheral nervous system neoplasm	2.79e-05	0.000802	CbGpPWpGaD
Paroxetine—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	2.75e-05	9.56e-05	CcSEcCtD
Paroxetine—CHRM4—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.75e-05	0.000792	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.74e-05	0.000789	CbGpPWpGaD
Paroxetine—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	2.73e-05	9.49e-05	CcSEcCtD
Paroxetine—CHRM3—Metabolism—COX2—peripheral nervous system neoplasm	2.68e-05	0.000772	CbGpPWpGaD
Paroxetine—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	2.66e-05	9.24e-05	CcSEcCtD
Paroxetine—Urticaria—Doxorubicin—peripheral nervous system neoplasm	2.65e-05	9.22e-05	CcSEcCtD
Paroxetine—CHRM4—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	2.65e-05	0.000762	CbGpPWpGaD
Paroxetine—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	2.64e-05	9.18e-05	CcSEcCtD
Paroxetine—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	2.64e-05	9.18e-05	CcSEcCtD
Paroxetine—CHRM5—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.64e-05	0.000758	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.63e-05	0.000755	CbGpPWpGaD
Paroxetine—Asthenia—Epirubicin—peripheral nervous system neoplasm	2.59e-05	9e-05	CcSEcCtD
Paroxetine—Pruritus—Epirubicin—peripheral nervous system neoplasm	2.56e-05	8.88e-05	CcSEcCtD
Paroxetine—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.55e-05	0.000734	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	2.54e-05	0.00073	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.53e-05	0.000728	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GNS—peripheral nervous system neoplasm	2.5e-05	0.00072	CbGpPWpGaD
Paroxetine—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	2.47e-05	8.58e-05	CcSEcCtD
Paroxetine—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	2.46e-05	0.000708	CbGpPWpGaD
Paroxetine—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	2.46e-05	8.55e-05	CcSEcCtD
Paroxetine—HTR2A—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.45e-05	0.000706	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.44e-05	0.000702	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	2.43e-05	0.0007	CbGpPWpGaD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	2.43e-05	0.0007	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.43e-05	0.0007	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.42e-05	0.000697	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.41e-05	0.000693	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	2.41e-05	0.000692	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.41e-05	0.000692	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—NME1—peripheral nervous system neoplasm	2.4e-05	0.00069	CbGpPWpGaD
Paroxetine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	2.4e-05	8.33e-05	CcSEcCtD
Paroxetine—Dizziness—Epirubicin—peripheral nervous system neoplasm	2.39e-05	8.3e-05	CcSEcCtD
Paroxetine—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.38e-05	0.000686	CbGpPWpGaD
Paroxetine—Pruritus—Doxorubicin—peripheral nervous system neoplasm	2.36e-05	8.21e-05	CcSEcCtD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	2.36e-05	0.000678	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.35e-05	0.000677	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	2.34e-05	0.000674	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.34e-05	0.000673	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	2.34e-05	0.000672	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.33e-05	0.000671	CbGpPWpGaD
Paroxetine—SLC6A3—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	2.31e-05	0.000665	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—COX2—peripheral nervous system neoplasm	2.31e-05	0.000664	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.31e-05	0.000664	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	2.3e-05	0.000663	CbGpPWpGaD
Paroxetine—Vomiting—Epirubicin—peripheral nervous system neoplasm	2.3e-05	7.98e-05	CcSEcCtD
Paroxetine—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	2.29e-05	7.94e-05	CcSEcCtD
Paroxetine—Rash—Epirubicin—peripheral nervous system neoplasm	2.28e-05	7.91e-05	CcSEcCtD
Paroxetine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	2.27e-05	7.9e-05	CcSEcCtD
Paroxetine—Headache—Epirubicin—peripheral nervous system neoplasm	2.26e-05	7.86e-05	CcSEcCtD
Paroxetine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	2.21e-05	7.68e-05	CcSEcCtD
Paroxetine—TACR1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.19e-05	0.00063	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.15e-05	0.000619	CbGpPWpGaD
Paroxetine—Nausea—Epirubicin—peripheral nervous system neoplasm	2.15e-05	7.45e-05	CcSEcCtD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	2.14e-05	0.000616	CbGpPWpGaD
Paroxetine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	2.12e-05	7.38e-05	CcSEcCtD
Paroxetine—CYP2C8—Metabolism—GNS—peripheral nervous system neoplasm	2.12e-05	0.000609	CbGpPWpGaD
Paroxetine—Rash—Doxorubicin—peripheral nervous system neoplasm	2.11e-05	7.32e-05	CcSEcCtD
Paroxetine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	2.1e-05	7.31e-05	CcSEcCtD
Paroxetine—Headache—Doxorubicin—peripheral nervous system neoplasm	2.09e-05	7.27e-05	CcSEcCtD
Paroxetine—HTR2A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.05e-05	0.000591	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.04e-05	0.000588	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.04e-05	0.000586	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—NME1—peripheral nervous system neoplasm	2.03e-05	0.000584	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.02e-05	0.00058	CbGpPWpGaD
Paroxetine—Nausea—Doxorubicin—peripheral nervous system neoplasm	1.98e-05	6.89e-05	CcSEcCtD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.98e-05	0.00057	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—COX2—peripheral nervous system neoplasm	1.95e-05	0.000562	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	1.94e-05	0.000559	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.92e-05	0.000554	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.9e-05	0.000547	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	1.89e-05	0.000544	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.87e-05	0.000537	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.86e-05	0.000535	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.86e-05	0.000534	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.85e-05	0.000532	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.85e-05	0.000532	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	1.85e-05	0.000531	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.84e-05	0.00053	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.83e-05	0.000527	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.83e-05	0.000525	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.82e-05	0.000524	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.8e-05	0.000517	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.79e-05	0.000514	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.78e-05	0.000512	CbGpPWpGaD
Paroxetine—SLC6A3—Neuronal System—HRAS—peripheral nervous system neoplasm	1.77e-05	0.000509	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	1.77e-05	0.000509	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.76e-05	0.000507	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ENO2—peripheral nervous system neoplasm	1.76e-05	0.000507	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	1.74e-05	0.0005	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	1.72e-05	0.000496	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	1.72e-05	0.000496	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.72e-05	0.000494	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	1.71e-05	0.000493	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	1.71e-05	0.000492	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.71e-05	0.000491	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	1.7e-05	0.00049	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.7e-05	0.000489	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.7e-05	0.000489	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.68e-05	0.000485	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.67e-05	0.000481	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	1.67e-05	0.00048	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	1.65e-05	0.000475	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.63e-05	0.000469	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.63e-05	0.000468	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.62e-05	0.000467	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.62e-05	0.000465	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	1.6e-05	0.000462	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.6e-05	0.000461	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.6e-05	0.000461	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.6e-05	0.000461	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	1.59e-05	0.000458	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.56e-05	0.000448	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.56e-05	0.000448	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.55e-05	0.000446	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.55e-05	0.000445	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.54e-05	0.000444	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	1.52e-05	0.000437	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ENO2—peripheral nervous system neoplasm	1.52e-05	0.000436	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—BCHE—peripheral nervous system neoplasm	1.49e-05	0.000428	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.48e-05	0.000427	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.42e-05	0.000409	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.42e-05	0.000409	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.41e-05	0.000407	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—TH—peripheral nervous system neoplasm	1.4e-05	0.000403	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.36e-05	0.000392	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.29e-05	0.000372	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.29e-05	0.000371	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ENO2—peripheral nervous system neoplasm	1.28e-05	0.000369	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.28e-05	0.000369	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—BCHE—peripheral nervous system neoplasm	1.28e-05	0.000368	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.28e-05	0.000368	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.27e-05	0.000364	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1.25e-05	0.000359	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.22e-05	0.000352	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.21e-05	0.000347	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—TH—peripheral nervous system neoplasm	1.2e-05	0.000346	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GNAS—peripheral nervous system neoplasm	1.14e-05	0.000329	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.13e-05	0.000326	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.13e-05	0.000324	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.12e-05	0.000323	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ABCB1—peripheral nervous system neoplasm	1.12e-05	0.000323	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	1.12e-05	0.000322	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.11e-05	0.00032	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.1e-05	0.000317	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.1e-05	0.000315	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.09e-05	0.000314	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—BCHE—peripheral nervous system neoplasm	1.08e-05	0.000312	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.08e-05	0.000311	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	1.05e-05	0.000303	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.05e-05	0.000303	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.05e-05	0.000302	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.04e-05	0.000301	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	1.04e-05	0.0003	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.04e-05	0.0003	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.03e-05	0.000298	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.03e-05	0.000297	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—TH—peripheral nervous system neoplasm	1.02e-05	0.000293	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.01e-05	0.000289	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.9e-06	0.000285	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	9.88e-06	0.000284	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GNAS—peripheral nervous system neoplasm	9.83e-06	0.000283	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ABCB1—peripheral nervous system neoplasm	9.65e-06	0.000278	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.64e-06	0.000277	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	9.63e-06	0.000277	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.59e-06	0.000276	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.56e-06	0.000275	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.47e-06	0.000272	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.46e-06	0.000272	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	9.46e-06	0.000272	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	9.45e-06	0.000272	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.01e-06	0.000259	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	8.9e-06	0.000256	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	8.88e-06	0.000256	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	8.83e-06	0.000254	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.49e-06	0.000244	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.42e-06	0.000242	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	8.37e-06	0.000241	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.36e-06	0.00024	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GNAS—peripheral nervous system neoplasm	8.32e-06	0.000239	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	8.3e-06	0.000239	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ABCB1—peripheral nervous system neoplasm	8.17e-06	0.000235	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.81e-06	0.000225	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.48e-06	0.000215	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	7.36e-06	0.000212	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	7.25e-06	0.000209	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	7.15e-06	0.000206	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CASP3—peripheral nervous system neoplasm	7.09e-06	0.000204	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	7.05e-06	0.000203	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	6.85e-06	0.000197	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	6.83e-06	0.000197	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.82e-06	0.000196	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.79e-06	0.000195	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.78e-06	0.000195	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	6.77e-06	0.000195	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.76e-06	0.000194	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	6.71e-06	0.000193	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.7e-06	0.000193	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.69e-06	0.000193	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.66e-06	0.000192	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	6.65e-06	0.000191	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.64e-06	0.000191	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.58e-06	0.000189	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.5e-06	0.000187	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.22e-06	0.000179	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.94e-06	0.000171	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.69e-06	0.000164	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.53e-06	0.000159	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.3e-06	0.000152	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.29e-06	0.000152	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.27e-06	0.000151	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.25e-06	0.000151	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.2e-06	0.00015	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.99e-06	0.000143	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.96e-06	0.000143	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.94e-06	0.000142	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.9e-06	0.000141	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.85e-06	0.00014	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.82e-06	0.000139	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.81e-06	0.000138	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.8e-06	0.000138	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.78e-06	0.000137	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.76e-06	0.000137	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.76e-06	0.000137	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.72e-06	0.000136	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.54e-06	0.000131	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.4e-06	0.000127	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.38e-06	0.000126	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.37e-06	0.000126	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.35e-06	0.000125	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.35e-06	0.000125	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.32e-06	0.000124	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.16e-06	0.00012	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.03e-06	0.000116	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.01e-06	0.000115	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.99e-06	0.000115	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.95e-06	0.000114	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.84e-06	0.00011	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.75e-06	0.000108	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.73e-06	0.000107	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.72e-06	0.000107	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.68e-06	0.000106	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.67e-06	0.000106	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AKT1—peripheral nervous system neoplasm	3.08e-06	8.87e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.08e-06	8.86e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.06e-06	8.81e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.05e-06	8.79e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.02e-06	8.7e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.95e-06	8.48e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.93e-06	8.43e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.92e-06	8.4e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.89e-06	8.32e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AKT1—peripheral nervous system neoplasm	2.65e-06	7.63e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.6e-06	7.48e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.59e-06	7.44e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.58e-06	7.42e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.55e-06	7.35e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AKT1—peripheral nervous system neoplasm	2.25e-06	6.46e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	1.96e-06	5.63e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	1.84e-06	5.31e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	1.83e-06	5.26e-05	CbGpPWpGaD
